61367-41-7 Usage
Description
Trans-4-Methoxycyclohexanamine Hydrochloride, also known as trans-4-MethoxycyclohexanaMine HCl, is an organic compound with the chemical formula C7H15NO2·HCl. It is a derivative of cyclohexanamine, featuring a methoxy group and a hydrochloride ion. trans-4-MethoxycyclohexanaMine HCl is known for its potential applications in the pharmaceutical industry, particularly in the synthesis of various compounds.
Uses
Used in Pharmaceutical Industry:
Trans-4-Methoxycyclohexanamine HCl is used as a synthetic intermediate for the development of novel anticancer agents. Its role in the synthesis process is crucial, as it contributes to the formation of analogs of N-?(2-?chloroethyl)?-?N''-?(trans-?4-?methylcyclohexyl)?-?N-?nitrosourea, which are known for their potential in combating cancer.
In the synthesis of these analogs, trans-4-Methoxycyclohexanamine HCl serves as a key building block, providing the necessary structural features that enable the development of effective anticancer drugs. These analogs have shown promise in targeting and treating various types of cancer, making trans-4-Methoxycyclohexanamine HCl an important compound in the ongoing fight against the disease.
Check Digit Verification of cas no
The CAS Registry Mumber 61367-41-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,1,3,6 and 7 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 61367-41:
(7*6)+(6*1)+(5*3)+(4*6)+(3*7)+(2*4)+(1*1)=117
117 % 10 = 7
So 61367-41-7 is a valid CAS Registry Number.
61367-41-7Relevant articles and documents
Compounds and methods of use
-
, (2021/08/04)
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, Y, A, L1, L2, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS
-
Page/Page column 106, (2015/02/25)
The present invention relates to benzimidazolyl-methyl urea derivatives of formula (I), wherein n, D, E, R1, R2, R3, R4, R6, R7, R8 and R9 are as defined in the description, their preparation and their use as pharmaceutically active compounds.
BRADYKININ 1 RECEPTOR ANTAGONISTS
-
Page/Page column 63, (2008/06/13)
The invention encompasses novel compounds and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for treatment of diseases mediated by B1 bradykinin receptor.